Union Health Minister to launch world’s first Made-in-India Nasal Covid Vaccine

Nasal vaccine is expected to be available in Indian markets from February next week. Recently, the company has also announced the use of iNCOVACC (BBV154) as a booster dose against the COVID-19 virus.

“iNCOVACC® is a recombinant replication-deficient adenovirus vector vaccine with a pre-fusion-stable SARS-CoV-2 spike protein. This vaccine candidate has been evaluated in Phase I, II and III clinical trials with successful results was done. iNCOVACC® has been done. Specially formulated to allow intranasal delivery via nasal drops. The nasal delivery system was designed and developed to be cost-effective in low- and middle-income countries Has been done.” read the statement for the company.

the cost of the vaccine 800 for private markets while Bharat Biotech has kept the price for supply to central and state governments 325. For the time being the nasal vaccine is not available on CoWin.

“We have achieved the goals we set for ourselves during this pandemic. We have developed two COVID vaccines COVAXIN® and iNCOVACC® from two different platforms with two different delivery systems. The vector intranasal delivery platform allows us to rapidly provides potential for development. Scale-up, easy and painless vaccination during public health emergencies and pandemics. We would like to thank the Ministry of Health, CDSCO, Department of Biotechnology, Government of India, Technology Development Board and Washington University, St. Louis for their support and Thank you for the guidance.” said Dr Krishna Ella, Executive Chairman.

Other senior representatives of the Central Government including senior ministers and officers will also be present on the occasion.

INCOVACC will be the first needle-free test to be given as a booster dose.

(With inputs from ANI)